Thank you for your letter 20 April in response to my enquiry dated 21 January about discrepancies between the SPC/Data Sheet for citalopram (Cipramil) and the approved US prescribing information for Celexa (citalopram).

Your letter confirmed for me that US prescribers tend to be better informed, and that the SPC/data sheet was indeed inaccurate in several respects. I also assume you were not aware of this until I wrote - therefore I was much perplexed by your reference to the sum of £245, your estimate of the cost to the MCA of enquiring into the anomalies identified. It seems to me this is a very modest sum to have invested in preventing the dissemination of inaccurate and potentially misleading information - and given the cost was so low, one might well wonder why the investment was not made long before we wrote.

I nevertheless appreciated your show of robust good humour, in suggesting it was gracious of the MCA not to bill us for £245. Don’t worry: even if on this occasion the MCA wouldn't have had a leg to stand on, you may be sure that I will always meet the Agency's charges when justified.